TScan Therapeutics (TCRX) Revenue & Revenue Breakdown
TScan Therapeutics Revenue Highlights
Latest Revenue (Y)
$21.05M
TScan Therapeutics Revenue by Period
TScan Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $21.05M | 55.52% |
| 2022-12-31 | $13.54M | 33.47% |
| 2021-12-31 | $10.14M | 834.65% |
| 2020-12-31 | $1.08M | 100.00% |
| 2019-12-31 | - | - |
TScan Therapeutics generated $21.05M in revenue during NA 2023, up 55.52% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
TScan Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $566.00K | -92.15% |
| 2023-12-31 | $7.21M | 85.52% |
| 2023-09-30 | $3.89M | 23.48% |
| 2023-06-30 | $3.15M | -53.73% |
| 2023-03-31 | $6.80M | 680200.00% |
| 2022-12-31 | $1.00K | -99.97% |
| 2022-09-30 | $3.36M | -17.09% |
| 2022-06-30 | $4.06M | 34.26% |
| 2022-03-31 | $3.02M | 5.85% |
| 2021-12-31 | $2.85M | 18.33% |
| 2021-09-30 | $2.41M | -15.31% |
| 2021-06-30 | $2.85M | 40.50% |
| 2021-03-31 | $2.03M | 154.97% |
| 2020-12-31 | $795.00K | 174.14% |
| 2020-09-30 | $290.00K | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
TScan Therapeutics generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
TScan Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| ARWR | Arrowhead Pharmaceuticals | $240.74M | - |
| VECT | VectivBio | $27.34M | $676.00K |
| TCRX | TScan Therapeutics | $21.05M | - |
| ITOS | iTeos Therapeutics | $12.60M | - |
| PRQR | ProQR Therapeutics | $6.38M | $4.48M |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| CGTX | Cognition Therapeutics | - | - |
| ANNX | Annexon | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| DRMA | Dermata Therapeutics | - | - |
TCRX Revenue FAQ
What is TScan Therapeutics’s yearly revenue?
TScan Therapeutics's yearly revenue for 2023 was $21.05M, representing an increase of 55.52% compared to 2022. The company's yearly revenue for 2022 was $13.54M, representing an increase of 33.47% compared to 2021. TCRX's yearly revenue for 2021 was $10.14M, representing an increase of 834.65% compared to 2020.
What is TScan Therapeutics’s quarterly revenue?
TScan Therapeutics's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $566K, a -92.15% decrease from the previous quarter (Q4 2023), and a -91.68% decrease year-over-year (Q1 2023). TCRX's quarterly revenue for Q4 2023 was $7.21M, a 85.52% increase from the previous quarter (Q3 2023), and a 721000.00% increase year-over-year (Q4 2022).
What is TScan Therapeutics’s revenue growth rate?
TScan Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 107.56%, and for the last 5 years (2019-2023) was 0%.